Nexalin Technology, Inc.
Nexalin Technology, Inc.
Your view on NXL
Overview
What the company does, where it operates, and who runs it.
About Nexalin Technology, Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Mark White
- Headquarters
- 1776 Yorktown, Houston, TX, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Mark White
- Headquarters
- 1776 Yorktown, Houston, TX, US
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia.
The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders.
It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Nexalin Technology, Inc., and the rating behind it. NXL last traded at $4.82; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Nexalin Technology, Inc.. Starting points for Nexalin Technology, Inc.: EPS -$12.75, beta 3.98 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Nexalin Technology, Inc.. Nexalin Technology, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Nexalin Technology, Inc.. Trailing twelve-month EPS for Nexalin Technology, Inc. stands at -$12.75. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Nexalin Technology, Inc.. Nexalin Technology, Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Nexalin Technology, Inc. valued side by side against its closest peers. Nexalin Technology, Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Nexalin Technology, Inc., and how their positions are changing. At a $3.5M market value, institutional positions materially move Nexalin Technology, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Nexalin Technology, Inc. executives and directors. Shares of Nexalin Technology, Inc. have traded between $0.70 and $4.49 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Nexalin Technology, Inc.. Nexalin Technology, Inc. is a $3.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Nexalin Technology, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Nexalin Technology, Inc.. Coverage tracks Nexalin Technology, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.